title: Down expression of LRP1B promotes cell migration via RhoA/Cdc42 pathway and actin cytoskeleton remodeling in renal cell cancer.
abstract: The low-density lipoprotein receptor-related protein 1B (LRP1B) is known as a putative tumor suppressor. The decreased expression of LRP1B has been involved in multiple primary cancers in several studies. However, its expression and function in the carcinogenesis of renal cell cancer (RCC) remain unclear. In this study, we investigated the expression of LRP1B in RCC by in situ hybridization (ISH) and real-time polymerase chain reaction (qRT-PCR). Our results indicated that LRP1B was frequently downexpressed in human RCC tissue and cell lines, which involved both epigenetic events (DNA methylation and histone deacetylation) and N-terminal deletion of LRP1B. Moreover, we testified that knockdown of LRP1B by shRNA significantly promoted anchorage-independent growth, cell migration and invasion in HEK293 cells and renal cancer cells 127 in vitro. We further found that silencing of LRP1B altered the expression of focal adhesion complex-associated proteins, and Cdc42/RhoA activities, which regulate the cytoskeleton dynamics. Taken together, these results strongly support that LRP1B may function as a tumor suppressor against renal cell cancer, and may regulate cell motility via RhoA/Cdc42 pathway and actin cytoskeleton reorganization in RCC.
authors.affiliation: School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
authors.forename: Shaobin
authors.initials: S
authors.lastname: Ni
authors.forename: Jianran
authors.initials: J
authors.lastname: Hu
authors.forename: Yongshun
authors.initials: Y
authors.lastname: Duan
authors.forename: Shuliang
authors.initials: S
authors.lastname: Shi
authors.forename: Ruo
authors.initials: R
authors.lastname: Li
authors.forename: Hongjin
authors.initials: H
authors.lastname: Wu
authors.forename: Youpeng
authors.initials: Y
authors.lastname: Qu
authors.forename: Yu
authors.initials: Y
authors.lastname: Li
mesh_terms: D000107:Acetylation; D008841:Actin Cytoskeleton / Q000235:genetics* / Q000378:metabolism; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics*; D019175:DNA Methylation / Q000235:genetics; D015536:Down-Regulation; D005260:Female; D051417:Focal Adhesion Kinase 1 / Q000235:genetics / Q000378:metabolism; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor; D057809:HEK293 Cells; D006657:Histones / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009361:Neoplasm Invasiveness; D011973:Receptors, LDL / Q000235:genetics* / Q000378:metabolism; D020764:cdc42 GTP-Binding Protein / Q000235:genetics* / Q000378:metabolism; D020742:rhoA GTP-Binding Protein / Q000235:genetics* / Q000378:metabolism
chemical_list: D006657:Histones; C434476:LRP1B protein, human; D011973:Receptors, LDL; C066737:RHOA protein, human; D051417:Focal Adhesion Kinase 1; C496050:PTK2 protein, human; D020764:cdc42 GTP-Binding Protein; D020742:rhoA GTP-Binding Protein